Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel GR antagonists discovered to prevent antipsychotic-induced weight gain

Dec. 13, 2012

uniQure begins phase I study in acute intermittent porphyria

Dec. 13, 2012

PDC Biotech completes phase I trial of PDC-13 in primary dysmenorrhea

Dec. 13, 2012

Catabasis Pharmaceuticals synthesizes novel inhibitors of NF-kappaB signaling

Dec. 13, 2012

New agents for obesity presented by Zafgen

Dec. 12, 2012

Isis Pharmaceuticals reports phase I data for three drugs

Dec. 11, 2012

Protalix initiates study of long-term enzyme replacement therapy for Fabry's disease

Dec. 11, 2012

Gedeon Richter synthesizes novel MCH1 receptor antagonists

Dec. 11, 2012

New triacylglycerol lipase inhibitors designed by Roche

Dec. 10, 2012

AEM-28 given orphan drug status by FDA

Dec. 10, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...